

# CONTENTS

## 10TH EDITION

Contributors .....	xiii
Preface .....	xxi
Acknowledgments .....	xxii

1. Historical Principles and Perspectives .....	1
<i>Paul M. Wax</i>	
2. Toxicologic Misfortunes and Catastrophes in History .....	16
<i>Paul M. Wax</i>	

### PART A

#### THE GENERAL APPROACH TO MEDICAL TOXICOLOGY

3. Initial Evaluation of the Patient: Vital Signs and Toxic Syndromes .....	26
<i>Robert S. Hoffman, Mary Ann Howland, Neal A. Lewin, Lewis S. Nelson, and Lewis R. Goldfrank</i>	
4. Principles of Managing the Acutely Poisoned or Overdosed Patient .....	30
<i>Robert S. Hoffman, Mary Ann Howland, Neal A. Lewin, Lewis S. Nelson, and Lewis R. Goldfrank</i>	
5. Diagnostic Imaging .....	38
<i>David T. Schwartz</i>	
6. Laboratory Principles .....	62
<i>Petrie M. Rainey</i>	
7. Medicolegal Interpretive Toxicology .....	76
<i>Robert A. Middleberg</i>	
8. Techniques Used to Prevent Gastrointestinal Absorption .....	83
<i>Lotte C. G. Hoegberg and Anne-Bolette Gude</i>	
41. ACTIVATED CHARCOAL .....	97
<i>Silas W. Smith and Mary Ann Howland</i>	
42. WHOLE-BOWEL IRRIGATION AND OTHER INTESTINAL EVACUANTS .....	104
<i>Silas W. Smith and Mary Ann Howland</i>	
9. Pharmacokinetic and Toxicokinetic Principles .....	110
<i>Mary Ann Howland</i>	
10. Principles and Techniques Applied to Enhance Elimination .....	124
<i>David S. Goldfarb and Marc Ghannoum</i>	
11. Use of the Intensive Care Unit .....	135
<i>Kyle B. Enfield and Mark A. Kirk</i>	

### PART B

#### THE FUNDAMENTAL PRINCIPLES OF MEDICAL TOXICOLOGY

### SECTION I

#### BIOCHEMICAL AND MOLECULAR BASIS

12. Chemical Principles .....	143
<i>Stephen J. Traub and Lewis S. Nelson</i>	
13. Biochemical and Metabolic Principles .....	155
<i>Kurt C. Kleinschmidt and Kathleen A. Delaney</i>	
Appendix: Cytochrome P450 Substrates, Inhibitors, and Inducers .....	168
14. Neurotransmitters and Neuromodulators .....	172
<i>Steven C. Curry, Ayrn D. O'Connor, Kimberlie A. Graeme, Kirk C. Mills, and Aaron B. Skolnik</i>	
15. Withdrawal Principles .....	202
<i>Richard J. Hamilton</i>	

### SECTION II

#### PATHOPHYSIOLOGIC BASIS: ORGAN SYSTEMS

16. Electrophysiologic and Electrocardiographic Principles .....	207
<i>Cathleen Clancy</i>	
17. Cardiac Principles II: Hemodynamics .....	222
<i>Robert A. Hessler</i>	
18. Dermatologic Principles .....	231
<i>Jesse M. Lewin, Neal A. Lewin, and Lewis S. Nelson</i>	
SC1. TRANSDERMAL TOXICOLOGY .....	245
<i>Lewis S. Nelson</i>	
19. Fluid, Electrolyte, and Acid-Base Principles .....	248
<i>Alan N. Charney and Robert S. Hoffman</i>	
20. Gastrointestinal Principles .....	262
<i>Matthew D. Zuckerman and Richard J. Church</i>	
21. Genitourinary Principles .....	272
<i>Jason Chu</i>	
22. Hematologic Principles .....	285
<i>Marco L.A. Sivilotti</i>	
23. Hepatic Principles .....	302
<i>Kathleen A. Delaney</i>	
24. Neurologic Principles .....	315
<i>Rama B. Rao</i>	
25. Ophthalmic Principles .....	324
<i>Adhi Sharma</i>	
26. Otolaryngologic Principles .....	331
<i>William K. Chiang</i>	
27. Psychiatric Principles .....	341
<i>Erin A. Zerbo and Andrea M. Kondracke</i>	
28. Renal Principles .....	356
<i>Marc Ghannoum and David S. Goldfarb</i>	
29. Respiratory Principles .....	366
<i>Andrew Stolbach and Robert S. Hoffman</i>	
30. Thermoregulatory Principles .....	377
<i>Susi U. Vassallo and Kathleen A. Delaney</i>	

### SECTION III

#### SPECIAL POPULATIONS

31. Reproductive and Perinatal Principles .....	395
<i>Jeffrey S. Fine</i>	
32. Pediatric Principles .....	415
<i>Jeffrey S. Fine</i>	
33. Geriatric Principles .....	428
<i>Judith C. Ahronheim and Mary Ann Howland</i>	
34. Postmortem Toxicology .....	437
<i>Rama B. Rao and Mark A. Flomenbaum</i>	
SC2. ORGAN PROCUREMENT FROM POISONED PATIENTS .....	444
<i>Rama B. Rao</i>	

### PART C

#### THE CLINICAL BASIS OF MEDICAL TOXICOLOGY

### SECTION I

#### A. ANALGESICS AND ANTIINFLAMMATORY MEDICATIONS

CASE STUDY 1 .....	446
35. Acetaminophen .....	447
<i>Robert G. Hendrickson</i>	
A3. N-ACETYLCYSTEINE .....	465
<i>Robert G. Hendrickson and Mary Ann Howland</i>	
36. Colchicine, Podophyllin, and the Vinca Alkaloids .....	473
<i>Joshua G. Schier</i>	



37. Nonsteroidal Antiinflammatory Drugs.....	484	<i>William J. Holubek</i>
38. Opioids.....	492	<i>Lewis S. Nelson and Dean Olsen</i>
<b>A4. OPIOID ANTAGONISTS.....</b>	<b>510</b>	<i>Lewis S. Nelson and Mary Ann Howland</i>
39. Salicylates.....	516	<i>Daniel M. Lugassy</i>
<b>A5. SODIUM BICARBONATE.....</b>	<b>528</b>	<i>Paul M. Wax</i>
<b>B. FOOD, DIET, AND NUTRITION</b>		
<b>CASE STUDY 2.....</b>	<b>536</b>	
40. Athletic Performance Enhancers.....	537	<i>Susi U. Vassallo</i>
41. Botulism.....	548	<i>Howard L. Geyer</i>
<b>A6. BOTULINUM ANTITOXIN.....</b>	<b>559</b>	<i>Silas W. Smith and Howard L. Geyer</i>
42. Dieting Xenobiotics and Regimens.....	564	<i>Jeanna M. Marraffa</i>
43. Essential Oils.....	575	<i>Lauren Kornreich Shawn</i>
44. Food Poisoning.....	586	<i>Michael G. Tunik</i>
45. Herbal Preparations.....	598	<i>Oliver L. Hung</i>
46. Iron.....	616	<i>Jeanmarie Perrone</i>
<b>A7. DEFEROXAMINE.....</b>	<b>623</b>	<i>Mary Ann Howland</i>
47. Vitamins.....	628	<i>Beth Y. Ginsburg</i>
<b>C. PHARMACEUTICALS</b>		
<b>CASE STUDY 3.....</b>	<b>643</b>	
48. Antiepileptics.....	645	<i>Suzanne Doyon</i>
<b>A8. L-CARNITINE.....</b>	<b>657</b>	<i>Mary Ann Howland</i>
49. Antihistamines and Decongestants.....	660	<i>Sophie Gosselin</i>
<b>A9. PHYSOSTIGMINE SALICYLATE.....</b>	<b>677</b>	<i>Mary Ann Howland</i>
50. Chemotherapeutics Overview.....	681	<i>Richard Y. Wang</i>
51. Chemotherapeutics: Methotrexate.....	689	<i>Richard Y. Wang</i>
<b>A10. FOLATES: LEUCOVORIN (FOLINIC ACID) AND FOLIC ACID.....</b>	<b>693</b>	<i>Mary Ann Howland</i>
<b>A11. GLUCARPIDASE (CARBOXYPEPTIDASE G<sub>2</sub>).....</b>	<b>698</b>	<i>Silas W. Smith</i>
<b>SC3. INTRATHECAL ADMINISTRATION OF XENOBIOTICS.....</b>	<b>703</b>	<i>Rama B. Rao</i>
<b>SC4. EXTRAVASATION OF CHEMOTHERAPEUTICS.....</b>	<b>711</b>	<i>Richard Y. Wang</i>
52. Miscellaneous Chemotherapeutics.....	714	<i>Richard Y. Wang</i>
53. Antidiabetics and Hypoglycemics.....	720	<i>George M. Bosse</i>
<b>A12. DEXTROSE (D-GLUCOSE).....</b>	<b>732</b>	<i>Larissa I. Velez and Kathleen A. Delaney</i>
<b>A13. OCTREOTIDE.....</b>	<b>738</b>	<i>Mary Ann Howland and Silas W. Smith</i>
54. Antimigraine Medications.....	743	<i>Jason Chu</i>
55. Pharmaceutical Additives.....	750	<i>Sean P. Nordt and Lisa E. Vivero</i>
56. Thyroid and Antithyroid Medications.....	763	<i>Nicole C. Bouchard</i>
<b>D. ANTIMICROBIALS</b>		
57. Antibacterials, Antifungals, and Antivirals.....	772	<i>Christine M. Stork</i>
58. Antituberculous Medications.....	787	<i>Christina H. Hernon</i>
<b>A14. PYRIDOXINE.....</b>	<b>797</b>	<i>Mary Ann Howland</i>
59. Antimalarials.....	800	<i>James David Barry</i>
<b>E. CARDIOPULMONARY MEDICATIONS</b>		
<b>CASE STUDY 4.....</b>	<b>812</b>	
60. Antithrombotics.....	814	<i>Betty C. Chen and Mark Su</i>
<b>A15. VITAMIN K<sub>1</sub>.....</b>	<b>836</b>	<i>Mary Ann Howland</i>
<b>A16. PROTAMINE.....</b>	<b>839</b>	<i>Mary Ann Howland</i>
<b>A17. HIGH-DOSE INSULIN EUGLYCEMIA.....</b>	<b>851</b>	<i>Samuel J. Stellpflug and William Kerns, II</i>
61. Calcium Channel Blockers.....	843	<i>David H. Jang and Francis Jerome DeRoos</i>
62. $\beta$ -Adrenergic Antagonists.....	856	<i>Jeffrey R. Brubacher</i>
<b>A18. GLUCAGON.....</b>	<b>870</b>	<i>Mary Ann Howland</i>
63. Miscellaneous Antihypertensives and Pharmacologically Related Agents.....	874	<i>Francis Jerome DeRoos</i>
64. Antidysrhythmics.....	885	<i>Lewis S. Nelson</i>
65. Cardioactive Steroids.....	895	<i>Jason B. Hack</i>
<b>A19. DIGOXIN-SPECIFIC ANTIBODY FRAGMENTS.....</b>	<b>904</b>	<i>Mary Ann Howland</i>
66. Methylxanthines and Selective $\beta_2$ -Adrenergic Agonists.....	909	<i>Robert J. Hoffman</i>
<b>F. ANESTHETICS AND RELATED MEDICATIONS</b>		
67. Local Anesthetics.....	921	<i>David R. Schwartz and Brian Kaufman</i>
<b>A20. INTRAVENOUS FAT EMULSION.....</b>	<b>931</b>	<i>Theodore C. Bania</i>
68. Inhalational Anesthetics.....	938	<i>Brian Kaufman</i>
69. Neuromuscular Blockers.....	945	<i>Kenneth M. Sutin</i>
<b>A21. DANTROLENE SODIUM.....</b>	<b>955</b>	<i>Kenneth M. Sutin</i>
<b>G. PSYCHOTROPICS</b>		
<b>CASE STUDY 5.....</b>	<b>958</b>	
70. Antipsychotics.....	960	<i>David Juurlink</i>

71. Cyclic Antidepressants .....	972	93. Chromium .....	1197
<i>Erica L. Liebelt</i>		<i>Steven B. Bird</i>	
72. Lithium .....	983	94. Cobalt .....	1202
<i>Howard A. Greller</i>		<i>Gar Ming Chan</i>	
73. Monoamine Oxidase Inhibitors .....	993	95. Copper .....	1210
<i>Alex F. Manini</i>		<i>Lewis S. Nelson</i>	
74. Sedative-Hypnotics .....	1002	96. Lead .....	1219
<i>David C. Lee</i>		<i>Diane P. Calello and Fred M. Henretig</i>	
<b>A22. FLUMAZENIL .....</b>	<b>1013</b>	<b>A26. SUCCIMER (2,3-DIMERCAPTOSUCCINIC ACID) .....</b>	<b>1235</b>
<i>Mary Ann Howland</i>		<i>Mary Ann Howland</i>	
75. Serotonin Reuptake Inhibitors and Atypical Antidepressants .....	1018	<b>A27. EDETATE CALCIUM DISODIUM (CaNa<sub>2</sub>EDTA) .....</b>	<b>1241</b>
<i>Christine M. Stork</i>		<i>Mary Ann Howland</i>	
H. SUBSTANCES OF ABUSE			
<b>CASE STUDY 6 .....</b>	<b>1029</b>	97. Manganese .....	1245
76. Amphetamines .....	1030	<i>Sari Soghoian</i>	
<i>David H. Jang</i>		98. Mercury .....	1250
77. Cannabinoids .....	1042	<i>Young-Jin Sue</i>	
<i>Jeff M. Lapoint</i>		99. Nickel .....	1259
78. Cocaine .....	1054	<i>John A. Curtis and David A. Haggerty</i>	
<i>Jane M. Prosser and Robert S. Hoffman</i>		100. Selenium .....	1266
<b>SC5. INTERNAL CONCEALMENT OF XENOBIOTICS .....</b>	<b>1064</b>	<i>Diane P. Calello</i>	
<i>Jane M. Prosser</i>		101. Silver .....	1271
<b>A23. BENZODIAZEPINES .....</b>	<b>1069</b>	<i>Melisa W. Lai Becker and Michele M. Burns</i>	
<i>Robert S. Hoffman, Lewis S. Nelson, and Mary Ann Howland</i>		102. Thallium .....	1276
79. Disulfiram and Disulfiramlike Reactions .....	1076	<i>Maria Mercurio-Zappala and Robert S. Hoffman</i>	
<i>Amit K. Gupta</i>		<b>A28. PRUSSIAN BLUE .....</b>	<b>1283</b>
80. Ethanol .....	1082	<i>Robert S. Hoffman</i>	
<i>Luke Yip</i>		103. Zinc .....	1288
<b>A24. THIAMINE HYDROCHLORIDE .....</b>	<b>1094</b>	<i>Nima Majlesi</i>	
<i>Robert S. Hoffman</i>		J. HOUSEHOLD PRODUCTS	
<b>SC6. ASSESSMENT OF ETHANOL INDUCED IMPAIRMENT .....</b>	<b>1101</b>	<b>CASE STUDY 8 .....</b>	<b>1294</b>
<i>Robert B. Palmer</i>		104. Antiseptics, Disinfectants, and Sterilants .....	1295
81. Ethanol Withdrawal .....	1108	<i>Paul M. Wax</i>	
<i>Jeffrey A. Gold and Lewis S. Nelson</i>		105. Camphor and Moth Repellents .....	1307
82. Hallucinogens .....	1114	<i>Hong K. Kim</i>	
<i>Jennifer L. Carey and Kavita M. Babu</i>		106. Caustics .....	1315
83. $\gamma$ -Hydroxybutyric Acid ( $\gamma$ -Hydroxybutyrate) .....	1124	<i>Jessica A. Fulton</i>	
<i>Brenna M. Farmer</i>		107. Hydrofluoric Acid and Fluorides .....	1324
84. Inhalants .....	1129	<i>Mark Su</i>	
<i>Heather Long</i>		<b>A29. CALCIUM .....</b>	<b>1330</b>
85. Nicotine .....	1138	<i>Mary Ann Howland</i>	
<i>Sari Soghoian</i>		108. Hydrocarbons .....	1334
86. Phencyclidine and Ketamine .....	1144	<i>David D. Gummin</i>	
<i>Ruben E. Olmedo</i>		109. Toxic Alcohols .....	1346
I. METALS			
<b>CASE STUDY 7 .....</b>	<b>1155</b>	<b>SC7. DIETHYLENE GLYCOL .....</b>	<b>1358</b>
87. Aluminum .....	1156	<i>Joshua G. Schier</i>	
<i>Brenna M. Farmer</i>		<b>A30. FOMEPIZOLE .....</b>	<b>1364</b>
88. Antimony .....	1161	<i>Mary Ann Howland</i>	
<i>Asim F. Tarabar</i>		<b>A31. ETHANOL .....</b>	<b>1369</b>
89. Arsenic .....	1168	<i>Mary Ann Howland</i>	
<i>Stephen W. Munday</i>		K. PESTICIDES	
<b>A25. DIMERCAPROL (BRITISH ANTI-LEWISITE OR BAL) .....</b>	<b>1181</b>	<b>CASE STUDY 9 .....</b>	<b>1373</b>
<i>Mary Ann Howland</i>		110. Barium .....	1378
90. Bismuth .....	1184	<i>Andrew Dawson</i>	
<i>Rama B. Rao</i>		111. Fumigants .....	1381
91. Cadmium .....	1188	<i>Shahin Shadnia</i>	
<i>Stephen J. Traub and Robert S. Hoffman</i>		112. Herbicides .....	1389
92. Cesium .....	1193	<i>Darren M. Roberts</i>	
<i>Zhanna Livshits</i>		113. Insecticides: Organic Phosphorus Compounds and Carbamates .....	1409
		<i>Michael Eddleston</i>	



A32. ATROPINE .....	1425	A40. SODIUM THIOSULFATE .....	1615
<i>Mary Ann Howland</i>		<i>Mary Ann Howland</i>	
A33. PRALIDOXIME.....	1429	A41. HYDROXOCOBALAMIN .....	1618
<i>Mary Ann Howland</i>		<i>Mary Ann Howland</i>	
114. Insecticides: Organic Chlorines, Pyrethrins/Pyrethroids, and Insect Repellents.....	1435	127. Methemoglobin Inducers.....	1622
<i>Michael G. Holland</i>		<i>Dennis P. Price</i>	
115. Sodium Monofluoroacetate and Fluoroacetamide .....	1449	A42. METHYLENE BLUE.....	1631
<i>Fermin Barrueto Jr.</i>		<i>Mary Ann Howland</i>	
116. Phosphorus.....	1452	128. Smoke Inhalation.....	1634
<i>Michael C. Beuhler</i>		<i>Nathan P. Charlton and Mark A. Kirk</i>	
117. Strychnine.....	1456	129. Nanotoxicology .....	1643
<i>Yiu-Cheung Chan</i>		<i>Silas W. Smith</i>	
L. NATURAL TOXINS AND ENVENOMATIONS			
CASE STUDY 10 .....	1460	N. DISASTER PREPAREDNESS	
118. Arthropods .....	1461	130. Risk Assessment and Risk Communication .....	1665
<i>In-Hei Hahn</i>		<i>Charles A. McKay</i>	
A34. ANTIVENOM: SPIDER .....	1480	131. Hazardous Materials Incident Response .....	1670
<i>Michael A. Darracq and Richard F. Clark</i>		<i>Bradley J. Kaufman</i>	
A35. ANTIVENOM: SCORPION .....	1484	132. Chemical Weapons .....	1678
<i>Michael A. Darracq and Richard F. Clark</i>		<i>Jeffrey R. Suchard</i>	
119. Marine Envenomations .....	1487	133. Biological Weapons.....	1691
<i>D. Eric Brush</i>		<i>Jeffrey R. Suchard</i>	
120. Mushrooms.....	1500	134. Radiation.....	1700
<i>Lewis R. Goldfrank</i>		<i>Joseph G. Rella</i>	
A36. SILIBININ.....	1515	A43. POTASSIUM IODIDE.....	1713
<i>Mary Ann Howland</i>		<i>Joseph G. Rella</i>	
121. Plants .....	1517	A44. PENTETIC ACID OR PENTETATE (ZINC OR CALCIUM) TRISODIUM (DTPA).....	1717
<i>Lewis S. Nelson and Lewis R. Goldfrank</i>		<i>Joseph G. Rella</i>	
122. Native (US) Venomous Snakes and Lizards.....	1537	SECTION II	
<i>Anne-Michelle Ruha and Anthony F. Pizon</i>		POISON CENTERS AND EPIDEMIOLOGY	
A37. ANTIVENOM: SNAKES (NATIVE [US] VENOMOUS [CROTALINE AND ELAPID]) .....	1547	CASE STUDY 12 .....	1720
<i>Anthony F. Pizon and Anne-Michelle Ruha</i>		135. Poison Prevention and Education.....	1722
SC8. EXOTIC NONNATIVE SNAKE ENVENOMATIONS .....	1552	<i>Lauren Schwartz</i>	
<i>Keith Boesen, Kelly A. Green Boesen, and Farshad "Mazda" Shirazi</i>		136. Poison Centers and Poison Epidemiology .....	1728
M. OCCUPATIONAL AND ENVIRONMENTAL TOXINS			
CASE STUDY 11 .....	1557	<i>Robert S. Hoffman</i>	
123. Industrial Poisoning: Information and Control.....	1559	137. International Perspectives on Medical Toxicology .....	1736
<i>Peter H. Wald</i>		<i>Sari Soghoian</i>	
124. Simple Asphyxiants and Pulmonary Irritants .....	1567	138. Principles of Epidemiology and Research Design.....	1744
<i>Lewis S. Nelson and Oladapo A. Odujebi</i>		<i>Alex F. Manini and Kevin C. Osterhoudt</i>	
125. Carbon Monoxide.....	1581	139. Drug Development, Adverse Drug Events, and Postmarketing Surveillance.....	1753
<i>Christian Tomaszewski</i>		<i>Louis R. Cantilena</i>	
A38. HYPERBARIC OXYGEN.....	1594	140. Medication Safety and Adverse Drug Events.....	1762
<i>Stephen R. Thom</i>		<i>Brenna M. Farmer</i>	
126. Cyanide and Hydrogen Sulfide.....	1602	141. Risk Management and Legal Principles .....	1772
<i>Christopher P. Holstege and Mark A. Kirk</i>		<i>Barbara M. Kirrane and Dainius A. Drukteinis</i>	
A39. SODIUM AND AMYL NITRITE .....	1612	Index.....	1779
<i>Mary Ann Howland</i>			